GC Medical Science Corporation
KKRX:1422803,500.00
KRW
-110.00
(-3.05%)
ISIN
KR7142280007
Return %
Stock
S&P 500
1Y
-13.90
14.39
3Y
-1.82
81.42
5Y
-58.03
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Yeon-Geun Kim
- Full Time Employees
- 131
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Yongin-si South Korea
- IPO Date
- Dec 17, 2014
- Website
- greencrossms.com
- Similar Companies
- Business
- GC Medical Science Corporation (KRX: 142280), an affiliate of the GC Group, develops, manufactures, and markets in-vitro diagnostic reagents, point-of-care testing equipment, and hemodialysis solutions. Originally established in 1972 as a diagnostic division within Green Cross Corporation and incorporated as an independent entity in 2004, the company is headquartered in Yongin-si, South Korea, with specialized production facilities in Eumseong and Jincheon. The company supplies clinical laboratories, hospitals, dialysis centers, veterinary clinics, and retail consumers across South Korea, Europe, the Asia-Pacific, the Middle East, and Latin America. The company operates through three principal business segments: In-Vitro Diagnostics, Diabetes and Metabolic Care, and Renal Care. Its product and service portfolio includes molecular diagnostic polymerase chain reaction (PCR) assays and rapid test kits under the GENEDIA brand for infectious diseases, respiratory viruses, and vector-borne pathogens; enzyme-linked immunosorbent assay (ELISA) diagnostic kits and clinical biochemistry reagents for laboratory screening; personal and professional blood glucose monitoring systems and test strips marketed under the CERA-CHEK brand; point-of-care glycated hemoglobin (HbA1c) analyzers and test cartridges under the GREENCARE A1c brand; point-of-care lipid profile analyzers; veterinary diagnostic products and blood glucose monitors marketed under the CERA-PET brand; and artificial kidney hemodialysis solutions, including liquid Part A and Part B formulations as well as domestically developed powdered hemodialysis agents. In recent corporate and strategic developments, the company officially updated its corporate name from Green Cross Medical Science Corporation to GC Medical Science Corporation. To optimize its operational structure and allocate resources toward high-growth diagnostics and renal care, the company divested its legacy blood bag manufacturing business. In renal care, GC Medical Science Corporation extended a multi-year supply agreement through 2028 with Baxter International to provide hemodialysis solutions and successfully commercialized HDB-San, South Korea's first domestically manufactured powdered hemodialysis formulation produced at its dedicated Eumseong manufacturing facility. In addition, the company secured European In Vitro Diagnostic Medical Devices Regulation (CE-IVDR) certification for its personal blood glucose monitoring system to support international market expansion and continues to advance point-of-care testing technologies integrated with wireless connectivity and digital health data management.